• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病的治疗。

Treatment of Parkinson's disease.

作者信息

Hely M A, Fung V S, Morris J G

机构信息

Department of Neurology, Westmead Hospital, Westmead, NSW, 2145, Australia.

出版信息

J Clin Neurosci. 2000 Nov;7(6):484-94. doi: 10.1054/jocn.2000.0766.

DOI:10.1054/jocn.2000.0766
PMID:11029227
Abstract

The aim of current treatment of Parkinson's disease is to ameliorate the symptoms while seeking to lessen the potential development of late levodopa complications. To this end, there is ample evidence that the early use of dopamine agonists is beneficial in younger Parkinsonian patients but monotherapy with dopamine agonists is for only a select few. Nonergot dopamine agonists offer the potential for fewer side effects. Lower dose levodopa therapy delays the onset and reduces severity of dyskinesia and end of dose failure. However levodopa remains the treatment of choice in Parkinson's disease and should not be restricted unnecessarily in patients with disability. There is no evidence that levodopa is toxic to dopaminergic neurons in people with Parkinson's disease. As yet, no drugs are of proven neuroprotective value. Dopamine agonists, catechol-o-methyltransferase inhibitors, amantadine and apomorphine have differing but beneficial roles in the management of levodopa side effects. Ablative surgery and deep brain stimulation of thalamus, globus pallidus and subthalamic nucleus are increasingly available but choice of procedure depends not just on patient symptomatology, but also on local experience and results. Ideally, deep brain stimulation is the treatment of choice as it offers less morbidity than bilateral ablative surgery, the possibility of postoperative adjustments and the potential for reversibility if better treatments become available.

摘要

当前帕金森病治疗的目标是缓解症状,同时力求减少左旋多巴晚期并发症的潜在发生。为此,有充分证据表明,早期使用多巴胺激动剂对年轻帕金森病患者有益,但仅少数患者可采用多巴胺激动剂单药治疗。非麦角类多巴胺激动剂副作用可能较少。较低剂量的左旋多巴治疗可延迟异动症的发生并减轻其严重程度,还可缓解剂末失效。然而,左旋多巴仍是帕金森病的首选治疗药物,对于有残疾的患者不应不必要地限制使用。没有证据表明左旋多巴对帕金森病患者的多巴胺能神经元有毒性。目前,尚无经证实具有神经保护作用的药物。多巴胺激动剂、儿茶酚-O-甲基转移酶抑制剂、金刚烷胺和阿扑吗啡在处理左旋多巴副作用方面具有不同但有益的作用。毁损性手术以及对丘脑、苍白球和丘脑底核进行深部脑刺激的方法越来越多,但手术方式的选择不仅取决于患者的症状,还取决于当地的经验和效果。理想情况下,深部脑刺激是首选治疗方法,因为与双侧毁损性手术相比,它的发病率更低,术后有可能进行调整,而且如果有更好的治疗方法,还具有可逆性的潜力。

相似文献

1
Treatment of Parkinson's disease.帕金森病的治疗。
J Clin Neurosci. 2000 Nov;7(6):484-94. doi: 10.1054/jocn.2000.0766.
2
Parkinson's disease: diagnosis and treatment.帕金森病:诊断与治疗
Am Fam Physician. 2006 Dec 15;74(12):2046-54.
3
Parkinson's disease therapy: treatment of early and late disease.帕金森病治疗:早期和晚期疾病的治疗
Chin Med J (Engl). 2001 Mar;114(3):227-34.
4
Treatment of levodopa-induced motor complications.左旋多巴诱发的运动并发症的治疗。
Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052.
5
Pharmacotherapy for Parkinson's disease.帕金森病的药物治疗
Pharmacotherapy. 2007 Dec;27(12 Pt 2):161S-173S. doi: 10.1592/phco.27.12part2.161S.
6
[Current treatment of Parkinson's disease: problems and controversies].[帕金森病的当前治疗:问题与争议]
Rev Med Suisse. 2005 May 4;1(18):1214, 1216-9.
7
[Initial treatment of Parkinson's disease].[帕金森病的初始治疗]
Rev Neurol. 1997 Aug;25 Suppl 2:S163-9.
8
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.药物洞察:帕金森病治疗中的持续多巴胺能刺激
Nat Clin Pract Neurol. 2006 Jul;2(7):382-92. doi: 10.1038/ncpneuro0222.
9
Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.最大限度提高左旋多巴治疗帕金森病的获益风险比。
Pharmacotherapy. 1999 Nov;19(11 Pt 2):162S-8S. doi: 10.1592/phco.19.17.162S.30884.
10
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.帕金森病的初始治疗:左旋多巴与多巴胺受体激动剂
J Neurol. 2002 Sep;249 Suppl 2:II25-9. doi: 10.1007/s00415-002-1205-3.

引用本文的文献

1
An update on the management of young-onset Parkinson's disease.青年帕金森病管理的最新进展。
Degener Neurol Neuromuscul Dis. 2013 Oct 4;2:53-62. doi: 10.2147/DNND.S34251. eCollection 2013.
2
Deciduous DPSCs Ameliorate MPTP-Mediated Neurotoxicity, Sensorimotor Coordination and Olfactory Function in Parkinsonian Mice.脱落型牙髓间充质干细胞改善 MPTP 诱导的帕金森病模型小鼠的神经毒性、感觉运动协调能力和嗅觉功能。
Int J Mol Sci. 2019 Jan 29;20(3):568. doi: 10.3390/ijms20030568.
3
Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions.
氧化应激与焦虑症的发生关系:对可能的治疗干预的启示。
Curr Neuropharmacol. 2014 Mar;12(2):120-39. doi: 10.2174/1570159X11666131120232135.
4
Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options.氧化应激与神经退行性疾病:抗氧化治疗选择的上下游研究综述。
Curr Neuropharmacol. 2009 Mar;7(1):65-74. doi: 10.2174/157015909787602823.
5
Parkinson's disease: genetics and beyond.帕金森病:遗传学及其他方面
Curr Neuropharmacol. 2007;5(2):99-113. doi: 10.2174/157015907780866893.
6
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.金属离子在神经退行性变中的关键作用:一种有前景的治疗策略的基础。
Br J Pharmacol. 2005 Dec;146(8):1041-59. doi: 10.1038/sj.bjp.0706416.
7
Neuropsychiatric aspects of Parkinson's disease: recent advances.帕金森病的神经精神方面:最新进展
Curr Psychiatry Rep. 2003 May;5(1):68-76. doi: 10.1007/s11920-003-0012-6.